GlassScriptPhysician profile
Jennifer R Ferrell
NPI 1902860406
$7,762.27
in general payments reported to CMS, 2019-2025
37 companies · $2,477 in 2025
The $2,477 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.16 · 2020: $335 · 2021: $662 · 2022: $1,501 · 2023: $1,739 · 2024: $997 · 2025: $2,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,200 · Travel and Lodging: $713 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,199.68 |
| Travel and Lodging | $713.12 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,837.71 | 2022-2025 | Freestyle Libre 3, Infinity |
| Otsuka America Pharmaceutical, INC. | $766.92 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Bayer Healthcare Pharmaceuticals INC. | $459.03 | 2022-2025 | |
| Glaxosmithkline, LLC. | $307.07 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $293.88 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $293.10 | 2021-2025 | |
| Lilly USA, LLC | $273.71 | 2021-2023 | Jardiance, Mounjaro, Emgality |
| Lundbeck LLC | $201.87 | 2023-2025 | Rexulti, Vyepti |
| Abbvie INC. | $198.63 | 2021-2025 | |
| Amgen INC. | $198.61 | 2021-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $193.03 | 2021-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $178.34 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Sk Life Science, INC. | $168.50 | 2020 | |
| Medtronic USA, INC. | $166.63 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.47 | 2021-2023 | Jardiance, Synjardy, Tradjenta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $111.53 | 2022-2024 | Quviviq |
| Harmony Biosciences LLC | $106.14 | 2023-2024 | Wakix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.45 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $82.77 | 2021-2025 | Spravato |
| Eisai INC. | $78.74 | 2021-2023 | |
| Dexcom, INC. | $75.33 | 2022-2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $73.88 | 2022-2024 | Omnipod |
| Astellas Pharma US INC | $66.80 | 2023-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $65.66 | 2022 | |
| Sunovion Pharmaceuticals INC. | $53.14 | 2022 | |
| Edwards Lifesciences Corporation | $47.10 | 2024 | |
| Boston Scientific Corporation | $29.84 | 2024 | |
| Halozyme INC | $29.36 | 2023 | |
| Alexion Pharmaceuticals, INC. | $25.10 | 2022 | |
| Nevro Corp. | $23.26 | 2022 | |
| Medtronic, INC. | $22.69 | 2022 | |
| Ucb, INC. | $19.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.29 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.94 | 2019 | |
| Melinta Therapeutics, LLC | $15.01 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.09 | 2025 | Zoryve |
| Currax Pharmaceuticals LLC | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.